Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia

Blood (2024) 144 (Supplement 1): 993.

https://doi.org/10.1182/blood-2024-201881

Published: 2024

Journal Articles

Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity

Ilaria Stefania Pagani, Vaidehi Krishnan, John Ouyang, Chung How Kok, BeiJun Chen, Elyse C Page, Phuong Dang, Verity A Saunders, Jane James, Kelly Lim, Naranie Shanmuganathan, Susan Branford, Charles Chuah, David T Yeung, Daniel Thomas, Timothy P Hughes, Sin Tiong Ong, David M Ross

Blood (2024) 144 (Supplement 1): 2715.

https://doi.org/10.1182/blood-2024-206591

Published: 2024

Journal Articles

Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

Ilaria S. Pagani, Naranie Shanmuganathan, Phuong Dang, Verity A. Saunders, Randall Grose, Chung H. Kok, Jane James, Molly Tolland, Jodi A. Braley, Haley K. Altamura, David T. Yeung, Susan Branford, Agnes S. M. Yong, Timothy P. Hughes, David M. Ross

Blood (2023) 142 (25): 2192–2197.

https://doi.org/10.1182/blood.2023021119

Published: 2023

Includes: Supplemental data

Journal Articles

Highly Sensitive Droplet Digital PCR to Identify CML Patients with a High Probability of Achieving Treatment-Free Remission

Liu Lu, Phuong Dang, Chung Hoow Kok, Verity A Saunders, Susan Branford, Timothy P. Hughes, David T Yeung

Blood (2021) 138 (Supplement 1): 2559.

https://doi.org/10.1182/blood-2021-151966

Published: 2021

Journal Articles

A Combination of CD302 gene Expression and 3-Months BCR-ABL1 Level Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib

Chung Hoow Kok, PhD BSc, Liu Liu, PhD BSc, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Verity A Saunders, Phuong Dang, Timothy P. Hughes, MDMBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 663.

https://doi.org/10.1182/blood-2019-125446

Published: 2019

Journal Articles

Integration of Multiple Bioassays Using Machine Learning to Identify High-Risk CP-CML Patients Treated with Frontline Imatinib

Chung Hoow Kok, PhD BSc, Sakrapee Paisitkriangkrai, PhD, David T Yeung, PhD BSc, FRACP, FRCPA MBBS, Liu Liu, PhD BSc, Verity A Saunders, Phuong Dang, Agnes S. M. Yong, MD PhD, Deborah L White, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2018-99-117633

Published: 2018

Journal Articles

Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)

David M Ross, MBBS, PhD FRACP, FRCPA, Ilaria S Pagani, PhD, Naranie Shanmuganathan, MBBS, John F Seymour, MBBS, PhD, Anthony K Mills, FRACP, FRCPA, MBBS, Robin J Filshie, PhDFRACP,FRCPA, Christopher K Arthur, MDFRACP,FRCPA,MBBS, Phuong Dang, Verity A Saunders, Jody Braley, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Deborah L White, PhD FFSc (RCPA), Andrew P Grigg, MBBS, MD FRACP, FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Susan Branford, PhD, Timothy P. Hughes, MD

Blood (2017) 130 (Supplement 1): 1597.

https://doi.org/10.1182/blood.V130.Suppl_1.1597.1597

Published: 2017

Journal Articles

High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment

Blood (2015) 126 (23): 1419.

https://doi.org/10.1182/blood.V126.23.1419.1419

Published: 2015

Journal Articles

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

David M. Ross, Susan Branford, John F. Seymour, Anthony P. Schwarer, Christopher Arthur, David T. Yeung, Phuong Dang, Jarrad M. Goyne, Cassandra Slader, Robin J. Filshie, Anthony K. Mills, Junia V. Melo, Deborah L. White, Andrew P. Grigg, Timothy P. Hughes

Blood (2013) 122 (4): 515–522.

https://doi.org/10.1182/blood-2013-02-483750

Published: 2013

Includes: Supplemental data

Journal Articles

The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial.

Deborah L White, PhD, Verity A Saunders, Amity Frede, Phuong Dang, Stephanie Zrim, Michael Philip Osborn, MB, BS, Paul Manley, PhD, Timothy Hughes, MD

Blood (2009) 114 (22): 507.

https://doi.org/10.1182/blood.V114.22.507.507

Published: 2009

Journal Articles

Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection

Alberto Cagigi, Frida Mowafi, Linh V. Phuong Dang, Klara Tenner-Racz, Ann Atlas, Sven Grutzmeier, Paul Racz, Francesca Chiodi, Anna Nilsson

Blood (2008) 112 (12): 4401–4410.

https://doi.org/10.1182/blood-2008-02-140426

Published: 2008

Journal Articles

CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study

Deborah L White, PhD, Verity A Saunders, Phuong Dang, Amity Frede, Laura Eadie, Simona Soverini, PhD, Fabrizio Quarantelli, Peter Lin, Mark Thornquist, Dong-Wook Kim, MD, PhD, Fabrizio Pane, MD, Giovanni Martinelli, Jerald Radich, Thea Kalebic, MD, Giuseppe Saglio, MD, Timothy Hughes, MD

Blood (2008) 112 (11): 3187.

https://doi.org/10.1182/blood.V112.11.3187.3187

Published: 2008

Journal Articles

Enhancing the Functional Activity of the OCT-1 Influx Pump May Overcome the Negative Impact of Low OCT-1 Activity in Imatinib Treated CML Patients

Deborah White, PhD, Phuong Dang, Kelvin Groot Obbink, Amity Frede, Chung Kok, Timothy P Hughes, MD, Richard D’Andrea, PhD

Blood (2008) 112 (11): 723.

https://doi.org/10.1182/blood.V112.11.723.723

Published: 2008

Journal Articles

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

Deborah L. White, Verity A. Saunders, Phuong Dang, Jane Engler, Amity Venables, Stephanie Zrim, Andrew Zannettino, Kevin Lynch, Paul W. Manley, Timothy Hughes

Blood (2007) 110 (12): 4064–4072.

https://doi.org/10.1182/blood-2007-06-093617

Published: 2007

Includes: Supplemental data

Journal Articles

In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.

Devendra K. Hiwase, MD, Deborah L. White, Verity A. Saunders, Phuong Dang, Amity Venables, Laura Eadie, Steph Zrim, L. Bik To, MD, Junia V. Melo, MD, Timothy P. Hughes, MD

Blood (2007) 110 (11): 1937.

https://doi.org/10.1182/blood.V110.11.1937.1937

Published: 2007

Journal Articles

Molecular Response to Imatinib Is Dependent on Dose in CML Patients with Low OCT-1 Influx Activity. Patients with High Activity May Respond Equally Well to Standard or Increased Dose Imatinib.

Deborah White, Verity Saunders, Phuong Dang, Amity Venables, Steph Zrim, John Reynolds, Steven Quinn, Andrew Zannettino, Timothy Hughes

Blood (2006) 108 (11): 738.

https://doi.org/10.1182/blood.V108.11.738.738

Published: 2006

Journal Articles

ABCB1 Overexpression May Predispose Imatinib Treated CML Patients to the Development of Abl Kinase Domain Mutations, and May Be an Important Contributor to Acquired Resistance.

Deborah White, Phuong Dang, Amity Venables, Verity Saunders, Stephanie Zrim, Andrew Zannettino, Peter Diamond, Steven Quinn, Luen Bik To, Timothy Hughes

Blood (2006) 108 (11): 2144.

https://doi.org/10.1182/blood.V108.11.2144.2144

Published: 2006

Journal Articles

OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

Deborah L. White, Verity A. Saunders, Phuong Dang, Jane Engler, Andrew C. W. Zannettino, Antony C. Cambareri, Steven R. Quinn, Paul W. Manley, Timothy P. Hughes

Blood (2006) 108 (2): 697–704.

https://doi.org/10.1182/blood-2005-11-4687

Published: 2006

Journal Articles

Low Baseline Intrinsic Sensitivity to Imatinib (High IC50) in CML Patients Is Due to Reduced Oct-1 Mediated Influx. Intrinsic Sensitivity to AMN107 Does Not Correlate with That of Imatinib and Uptake of AMN107 Is Not Oct-1 Mediated.

Deborah L. White, Verity A. Saunders, Jane Engler, Phuong Dang, Andrew C.W. Zannettino, Antony Cambareri, Steven Quinn, Paul Manley, Timothy P. Hughes

Blood (2005) 106 (11): 1081.

https://doi.org/10.1182/blood.V106.11.1081.1081

Published: 2005

NARROW

Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia

Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity

Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

Highly Sensitive Droplet Digital PCR to Identify CML Patients with a High Probability of Achieving Treatment-Free Remission

A Combination of CD302 gene Expression and 3-Months BCR-ABL1 Level Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib

Integration of Multiple Bioassays Using Machine Learning to Identify High-Risk CP-CML Patients Treated with Frontline Imatinib

Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)

High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial.

Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection

CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study

Enhancing the Functional Activity of the OCT-1 Influx Pump May Overcome the Negative Impact of Low OCT-1 Activity in Imatinib Treated CML Patients

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.

Molecular Response to Imatinib Is Dependent on Dose in CML Patients with Low OCT-1 Influx Activity. Patients with High Activity May Respond Equally Well to Standard or Increased Dose Imatinib.

ABCB1 Overexpression May Predispose Imatinib Treated CML Patients to the Development of Abl Kinase Domain Mutations, and May Be an Important Contributor to Acquired Resistance.

OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

Low Baseline Intrinsic Sensitivity to Imatinib (High IC50) in CML Patients Is Due to Reduced Oct-1 Mediated Influx. Intrinsic Sensitivity to AMN107 Does Not Correlate with That of Imatinib and Uptake of AMN107 Is Not Oct-1 Mediated.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only